Abstract
Background
Recent investigations have proposed the potential role of gamma-aminobutyric acid (GABA) in regulating motility and immunity of the gastrointestinal system.
Aims
We aimed to investigate the anti-inflammatory effects of ivermectin (IVM) through GABAB receptors following acetic acid-induced colitis in rats.
Methods
In a controlled experimental study, we enrolled 78 male Wistar rats (13 groups; 6 rats/group). After colitis induction using acetic acid (4%), IVM, baclofen (a standard GABAB agonist) or the combination of both agents was delivered to rats orally (by gavage), with the same dosage continued for 5 days. The control group received the vehicle, and prednisolone (a standard anti-inflammatory agent) was administered in a separate group as the positive control. Colon samples were collected on the sixth day for histopathological evaluations and measurement of myeloperoxidase (MPO) activity, TNF-α levels, and p-NF-ĸB p65, COX-2 and iNOS expression levels.
Results
The greatest recovery was found after administering IVM 0.5, baclofen 0.5, or IVM 0.2 + baclofen 0.2 mg/kg/day (ulcer index [UI] = 1.4 ± 0.4, 1.7 ± 0.6, and 1.4 ± 0.3, respectively; p < 0.001 vs. the control [UI = 6.5 ± 0.7]). Histopathological evaluations revealed a significant decrease in the inflammation severity in the three above-mentioned groups. P-NF-ĸB p65, COX-2, and iNOS expression, MPO activity, and TNF-α levels also decreased dramatically following treatment with IVM 0.5, baclofen 0.5, or the combination therapy (p < 0.001 vs. the control).
Conclusions
IVM exerted promising anti-inflammatory effects in treating acetic acid-induced colitis in rats. Its synergistic effect with baclofen also signified the possible involvement of GABAB receptors in this process.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42.
Tasdemir S, Parlakpinar H, Vardi N, Kaya E, Acet A. Effect of endogen-exogenous melatonin and erythropoietin on dinitrobenzene sulfonic acid–induced colitis. Fundam Clin Pharmacol 2013;27:299–307.
Xavier R, Podolsky D. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427–434.
Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:928–937.
Monteleone G, Pallone F, MacDonald TT. Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol 2011;11:640–645.
Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin Immunol 2009;132:1–9.
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet 2007;369:1641–1657.
Dejban P, Sahraei M, Chamanara M, Dehpour A, Rashidian A. Anti-inflammatory effect of amitriptyline in a rat model of acetic acid-induced colitis: the involvement of the TLR4/NF-kB signaling pathway. Fundam Clin Pharmacol. 2020.
Motavallian A, Bouzari S, Zamani E, Karimian P, Dabirian S, Molavi M, Torshkooh FA. An investigation of the anti-inflammatory effects of gabapentin on acetic acid-induced colitis in rats. Mol Biol Rep. 2021. https://doi.org/10.1007/s11033-021-06357-2.
Tabary M, Aryannejad A, Noroozi N, Tavangar SM, Jafari RM, Araghi F, Dadkhahfar S, Dehpour AR. Ivermectin increases random-pattern skin flap survival in rats: the novel role of GABAergic system. J Surg Res 2021;259:431–441.
Aggarwal S, Ahuja V, Paul J. Attenuated GABAergic signaling in intestinal epithelium contributes to pathogenesis of ulcerative colitis. Dig Dis Sci 2017;62:2768–2779. https://doi.org/10.1007/s10620-017-4662-3.
Yan S, Ci X, Chen N, Chen C, Li X, Chu X, Li J, Deng X. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflam Res 2011;60:589–596.
Risks NIoHOfPfR, Association AREN. Institutional Animal Care and Use Committee Guidebook. vol 92. US Department of Health and Human Services, Public Health Service, National. 1992.
Rashidian A, Muhammadnejad A, Dehpour A-R, Mehr SE, Akhavan MM, Shirkoohi R, Chamanara M, Mousavi S-E, Rezayat S-M. Atorvastatin attenuates TNBS-induced rat colitis: the involvement of the TLR4/NF-kB signaling pathway. Inflammopharmacology 2016;24:109–118.
Underwood W, Anthony R. AVMA guidelines for the euthanasia of animals. Retrieved March 2020;2013:2020–2021.
Franek M, Vaculin S, Rokyta R. GABA~ B receptor agonist baclofen has non-specific antinociceptive effect in the model of peripheral neuropathy in rat. Physiol Res 2004;53:351–355.
Witaicenis A, Luchini AC, Hiruma-Lima CA, Felisbino SL, Garrido-Mesa N, Utrilla P, Gálvez J, di Stasi LC. Suppression of TNBS-induced colitis in rats by 4-methylesculetin, a natural coumarin: comparison with prednisolone and sulphasalazine. Chemico Biol Interact 2012;195:76–85.
Yousefi-Ahmadipour A, Rashidian A, Mirzaei MR, Farsinejad A, PourMohammadi-Nejad F, Ghazi-Khansari M, Ai J, Shirian S, Allahverdi A, Saremi J. Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: The S1P pathway. J Cell Physiol 2019;234:11078–11091.
El-Salhy M, Umezawa K. Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats. Int J Mol Med 2016;37:1457–1464.
Deshmukh C, Veeresh B, Pawar A. Protective effect of Emblica officinalis fruit extract on acetic acid induced colitis in rats. J Herbal Med Toxicol 2010;4:83–87.
Rashidian A, Mehrzadi S, Ghannadi AR, Mahzooni P, Sadr S, Minaiyan M. Protective effect of ginger volatile oil against acetic acid-induced colitis in rats: a light microscopic evaluation. J Integr Med 2014;12:115–120.
Rezayat SM, Dehpour A-R, Motamed SM, Yazdanparast M, Chamanara M, Sahebgharani M, Rashidian A. Foeniculum vulgare essential oil ameliorates acetic acid-induced colitis in rats through the inhibition of NF-kB pathway. Inflammopharmacology 2018;26:851–859.
Jurjus AR, Khoury NN, Reimund J-M. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004;50:81–92.
Rashidian A, Keshavarz-Bahaghighat H, Abdollahi A, Chamanara M, Faghir-Ghanesefat H, Hoseini-Ahmadabadi M, Dehpour AR. Agmatine ameliorates acetic acid-induced colitis in rats: involvement of nitrergic system. Immunopharmacol Immunotoxicol 2019;41:242–249.
Rashidian A, Rashki A, Abdollahi A, Haddadi N-S, Chamanara M, Mumtaz F, Dehpour AR. Dapsone reduced acetic acid-induced inflammatory response in rat colon tissue through inhibition of NF-kB signaling pathway. Immunopharmacol Immunotoxicol 2019;41:607–613.
Roberts E, Frankel S. γ-Aminobutyric acid in brain: its formation from glutamic acid. J Biol Chem 1950;187:55–63.
Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Pharmacol Rev 2008;60:243–260.
Ma X, Sun Q, Sun X, Chen D, Wei C, Yu X, Liu C, Li Y, Li J. Activation of GABAA receptors in colon epithelium exacerbates acute colitis. Front Immunol 2018;9:987.
Uezono Y, Kaibara M, Hayashi H, Kawakami S, Enjoji A, Kanematsu T, Taniyama K. Characterization of GABAB receptor in the human colon. J Pharmacol Sci 2004;94:211–213.
Jin Z, Mendu SK, Birnir B. GABA is an effective immunomodulatory molecule. Amino Acids 2013;45:87–94.
Piechota-Polanczyk A, Fichna J. The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn-Schmiedeberg’s Archiv Pharmacol 2014;387:605–620.
Duthey B, Hübner A, Diehl S, Boehncke S, Pfeffer J, Boehncke WH. Anti-inflammatory effects of the GABAB receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol 2010;19:661–666.
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521–533.
Dionne S, Hiscott J, D’agata I, Duhaime A, Seidman E. Quantitative PCR analysis of TNF-α and IL-1β mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci 1997;42:1557–1566. https://doi.org/10.1023/A:1018895500721.
Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012;91:635–646.
Neurath MF, Pettersson S, Zum Büschenfelde K-HM, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in mice. Nat Med 1996;2:998–1004.
Liu F, Zhang Y-Y, Song N, Lin J, Liu M-k, Huang C-L, Zhou C, Wang H, Wang M, Shen J-F. GABAB receptor activation attenuates inflammatory orofacial pain by modulating interleukin-1β in satellite glial cells: Role of NF-κB and MAPK signaling pathways. Brain Res Bull 2019;149:240–250.
Ardite E, Panes J, Miranda M, Salas A, Elizalde J, Sans M, Arce Y, Bordas J, Fernández-Checa J, Pique J. Effects of steroid treatment on activation of nuclear factor κB in patients with inflammatory bowel disease. Br J Pharmacol 1998;124:431–433.
Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010;29:781–788. https://doi.org/10.1038/onc.2009.421.
Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004;113:427–437. https://doi.org/10.1111/j.1365-2567.2004.01984.x.
Dudhgaonkar SP, Tandan SK, Kumar D, Raviprakash V, Kataria M. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. Inflammopharmacology 2007;15:188–195. https://doi.org/10.1007/s10787-007-1603-3.
Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E. The TNBS-induced colitis animal model: an overview. Ann Med Surg 2016;11:9–15.
Yamada T, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology 1992;102:1524–1534.
Acknowledgment
This study was supported by a grant from the Experimental Medicine Research Center, Tehran University of Medical Sciences (Grant No. 99-1-209-48299). The authors also want to thank the Iran National Science Foundation (INSF) for their kind support.
Funding
This study was supported by a grant from the Experimental Medicine Research Center, Tehran University of Medical Sciences (Grant No. 99-1-209-48299).
Author information
Authors and Affiliations
Contributions
Study conception and design: AD; acquisition of data: AA, MT, NN, SMT; analysis and interpretation of data: AA, MT, AR, RM; drafting of the manuscript: AA, MT, BM, AD, SI; critical revision: AD, AR.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval
All experiments were carried out according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8523, revised in 2011). All the study protocols were also approved by the Ethics in Medical Research Committee of Tehran University of Medical Sciences (No. IR.TUMS.MEDICINE.REC.1399.135) and were therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Aryannejad, A., Tabary, M., Noroozi, N. et al. Anti-inflammatory Effects of Ivermectin in the Treatment of Acetic Acid-Induced Colitis in Rats: Involvement of GABAB Receptors. Dig Dis Sci 67, 3672–3682 (2022). https://doi.org/10.1007/s10620-021-07258-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-021-07258-x